Press release
Number of voting rights and shares as of February 28, 2017
07 Mar 2017 18:09 CET
Company Name
FR0004032746-ALXP
ISIN
FR0004032746
Total number of voting rights and shares
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 222-16 of the Règlement Général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority).
|
Date |
Total number of shares |
Number of existing voting rights (GROSS) |
Number of existing voting rights (NET) |
|
02/28/2017 |
45,925,511 |
47,596,279 |
43,231 ,602 |
*Including 800,000 new shares in accordance with the contract of Equity line financing concluded with Kepler Cheuvreux on November 20th 2014, for a total amount of 655,000€. A shareholder holding 1.0% of the Company share capital (January 31st, 2017) would be reduced to approximately 0, 98% of the capital on non-diluted basis. A total of 2,960,000 new shares have been issued since the beginning of the second tranche”
About Neovacs
Created in 1993, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.
For more information on Neovacs, visit www.neovacs.fr
NEOVACS – Investor Relations
Charlène Masson
+33 (0)1 53 10 93 00
Investor Relations / Financial Communications – Life Science Advisors
Chris Maggos
Connect_neovacs_regulated-information-reglementee31012017.pdf